Science continues to make strides at slowing disease progression. Eagle Pharmaceuticals and the University of Pennsylvania have agreed to a licensing agreement for the development of dantrolene sodium for the potential treatment of people living with Alzheimer’s disease, including an agreement to fund additional research in January of 2020. Essentially, the study will be looking at dantrolene’s role in changing intracellular calcium levels or calcium signaling, which involves complex cellular pathways and may lead to neurodegeneration and neuron death. I lived with my grandmother for a few years back in the earlier 90s in the latter stages of the disease that took her brain, but not her humor. For my grandmother’s story, and that of a good friend of mine who developed Alzheimer’s in his 40s, click here.